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Background
Detection of HTLV infection continues to be important
to control spread of human retroviruses and to protect
safety of blood supply. The ARCHITECT rHTLV-I/II
assay is a chemiluminescence-based immunoassay,
which utilizes HTLV-I, and HTLV-II recombinant anti-
gens and peptides in a double-antigen-sandwich assay
format on the Abbott ARCHITECT automated platform.
Precision, sensitivity and specificity of the ARCHITECT
rHTLV-I/II assay is being presented.
Methods
Assay performance was evaluated on confirmed HTLV-
I/II positive specimens and specimens from German
Blood Donors and hospitalized patients. External perfor-
mance evaluation was conducted at two different sites
in Portugal. Murex HTLV-I/II EIA was used as com-
parator assay and INNO-LIA or MP diagnostics HTLV
Blot were used for confirmation.
Results
The ARCHITECT rHTLV-I/II assay detected all HTLV-
I and HTLV-II specimens (N=406) in accordance to the
Murex assay. Analytical sensitivity was equivalent to
Murex based on end-point-dilutions. Specificity on
HTLV-I/II blood donors was 99.95% (N=5646; 95% CI
99.84-99.99%), SD to cut-off was 15.6. Specificity on a
diagnostic population was 99.86% (N= 692; CI 95%
99.20-100%). Precision for samples (1-6 S/CO) was 3.98-
4.31%. Presented data support selected cut-off multi-
plier-value of 0.25 for the ARCHITECT rHTLV-I/II
assay. Results from the Receiver-Operating-Curve
showed a 99.98% area under the curve which is
indicative of high separation power between negative
and positive populations.
Conclusions
This study demonstrated excellent sensitivity and speci-
ficity of the ARCHITECT rHTLV-I/II assay. The assay
is suitable for both blood screening and diagnosis of
HTLV infections and therefore reduces risk of transfu-
sion transmitted HTLV and improves safety of blood
supply.
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